CDK4/6 inhibitorFDA-approvedFirst-line
Ribociclib
How it works
Blocks the CDK4/6 enzymes, which are involved in cell growth and division.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Ribociclib has been shown to improve progression-free survival in patients with hormone receptor-positive metastatic breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Studying Ribociclib and Chemotherapy for High-Risk Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing a Combination Treatment for HER2 Positive Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Comparing a New Therapy to Chemotherapy for Early Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Evaluating Leucogen to Prevent Low White Blood Cell Count in Breast Cancer Patients Taking Ribociclib | Breast Cancer | phase-2 | — | Source → |
| Evaluating a New Treatment Combination for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Ribociclib and Hormone Therapy in Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Assessing the Effectiveness and Safety of Ribociclib in Breast Cancer Treatment | Breast Cancer | preclinical | — | Source → |
| Evaluating Patient Outcomes with Ribociclib in Early-Stage Breast Cancer | Breast Cancer | preclinical | — | Source → |
| Study of Ribociclib and Hormone Therapy in Early Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing Letrozole and Ribociclib in Early Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Cyclin Dependent Kinase Inhibitors in Metastatic Breast Cancer | Breast Cancer | observational | In patients receiving palbociclib, a better median progression-free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). | Source → |
| Ribociclib and Letrozole Effective in Older Women with Advanced Breast Cancer | Breast Cancer | preclinical | The median progression-free survival was 36 months, and the breast cancer-specific survival rate at 24 and 36 months was 82% and 75%, respectively. | Source → |
| Combining Ferulic Acid with Breast Cancer Drugs May Improve Treatment | Breast Cancer | lab-study | — | Source → |
| New Nanoparticle Delivery System for Breast Cancer Treatment | Breast Cancer | lab-study | The RIB-LNC exhibited a 1.31-fold and 3.09-fold reduction in IC values in MDA-MB-231 and MCF-7 cells, respectively, as compared to free RIB. | Source → |
| New Treatment Combination Approved for High-Risk Breast Cancer | Breast Cancer | phase-3 | The invasive disease-free survival at 36 months was 90.7% for Ribo + AI versus 87.6% for AI, with a hazard ratio of 0.75. | Source → |
| CDK4/6 Inhibitors Linked to Cardiotoxic Events in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Ribociclib Improves Survival in Early Breast Cancer | Breast Cancer | phase-3 | At 3 years, invasive disease-free survival was 90.4% with ribociclib plus an NSAI and 87.1% with an NSAI alone. | Source → |
| CDK4/6 Inhibitors and Endocrine Therapy for Metastatic Breast Cancer | Breast Cancer | phase-3 | Ribociclib combined with letrozole significantly improved PFS over letrozole alone. | Source → |
| Targeted Liposomes Deliver Cancer Drug to Breast Cancer Cells | Breast Cancer | lab-study | — | Source → |
| Comparing Two Cancer Treatments in Younger Women | Breast Cancer | observational | The median progression-free survival was 24.05 months for palbociclib and 24.41 months for ribociclib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.